Investors in the vulnerable global economy constantly seek the Holy Grail: stocks immune to economic downturns. As the stock markets sway with economic and geopolitical uncertainty winds, finding those rare diamonds can feel like navigating a labyrinth blindfolded.However, seven solid companies weather the storm amidst the chaos and emerge stronger. Below are seven stocks of resilience, each a beacon of stability and growth in tumultuous times.Read more to delve into these corporations’ fundamentals, triump ...

In the latest trading session, Abbott (ABT) closed at $119.02, marking a +0.98% move from the previous day. The stock's change was less than the S&P 500's daily gain of 2.11%. Elsewhere, the Dow saw an upswing of 1.18%, while the tech-heavy Nasdaq appreciated by 2.96%.The the stock of maker of infant formula, medical devices and drugs has risen by 6.41% in the past month, leading the Medical sector's gain of 3.98% and the S&P 500's gain of 3.08%.The upcoming earnings release of Abbott will be of great inter ...

Abbott Laboratories reported strong earnings Wednesday, despite spending recent months responding to ... [+] criticism over problems that led to the shutdown of one of its infant formula-producing plants. (Stacey Wescott/Chicago Tribune/Tribune News Service via Getty Images)TNSAbbott (NYSE: ABT) reported its Q4 results last month, with revenues above and earnings aligning with the street estimates. The company reported revenue of $10.24 billion and earnings of $1.19 on a per-share and adjusted basis, compar ...

分组1 - Humana宣布每股派息0.885美元，将于2024年4月26日支付给股东[1] 分组2 - FedEx董事会宣布每股派息1.26美元，将于2024年4月1日支付给股东[2] 分组3 - Coca-Cola董事会批准公司第62次连续年度股息增长，每股季度股息从46美分增加至48.5美分，相当于每股年度股息从1.84美元增加至1.94美元[4]

股息支付 - Abbott公司董事会宣布每股派息为55美分[1] - 自1924年以来，这是Abbott连续支付的第401个季度股息[2] - Abbott已连续52年增加股息支付，并是标普500股息贵族指数的成员[3]

公司运营 - Abbott的全球供应链在COVID-19大流行和宏观经济条件的挑战下有所改善，目前没有重大的原材料或供应短缺问题[18] - Abbott拥有或持有大量专利和专利申请，以及重要商标，这些被认为对Abbott业务的运作至关重要[19] - Abbott的业务没有重大的季节性因素，也没有单一客户会对其产生重大不利影响[20] - Abbott相信其运营在环保法律和法规方面都符合要求，对环境保护的资本和运营支出在2023年并不重大，预计在2024年也不会有重大影响[21] 人力资源管理 - Abbott的员工中，69%在美国以外，女性占美国员工的47%，全球员工的46%，管理人员的42%[22] - Abbott有一个全球人才管理流程，旨在识别和评估组织内的人才，并为员工提供平等和一致的发展机会[23] - Abbott致力于发展一个对所有人包容的工作场所，将高管薪酬与人力资本管理相关联，以维持一个包容的文化和对员工的公平对待[24] - Abbott的员工网络在全球所有运营中发挥着重要作用，提供专业发展计划，其中58%的参与者是女性[25] - Abbott每年为数百名大学生提供有薪实习，其中59%是女性，61%是少数族裔[26] 监管和风险 - Abbott的产品开发、生产、销售、推广和分销受到美国食品和药物管理局（FDA）等国际监管机构的全面监管[29] - 在COVID-19公共卫生紧急情况期间，许多与流行病相关的产品（包括诊断测试）被监管机构授权在紧急情况下使用[29] - Abbott将继续监测相关美国政府机构的进一步监管行动，并评估对与流行病相关的政府政策和产品授权的潜在影响[30] - 美元兑其他货币的波动可能会影响Abbott的资产和负债的报告价值，以及其现金流量[53] - 美国和国际税收法律、法规和解释的不利变化可能会对Abbott的有效税率、财务状况和业务结果产生重大不利影响[54] - 全球公共卫生危机对Abbott的业务、财务状况和运营结果产生了实质性影响[55] - COVID-19诊断测试领域的FDA紧急使用授权(EUA)对Abbott的业务产生了影响[56] - Abbott的国际业务面临额外的风险，可能导致其收入和盈利能力下降[57] - 多种因素可能对Abbott未来的盈利能力和财务状况产生实质性不利影响[58] - 俄罗斯入侵乌克兰导致的政治不稳定、制裁、经济和货币波动等因素可能对Abbott的运营和财务状况产生重大不利影响[60]

Abbott Laboratories ABT, -1.06% said that a Food and Drug Administration panel voted in favor of the safety profile of its heart device TriClip. The medical device company on Tuesday said that the Circulatory System Devices Panel of the Medical Devices Advisory Committee also confirmed the effectiveness and risk/benefit profile of the device to treat people with tricuspid regurgitation. Tricuspid regurgitation is a type of heart valve disease that occurs when the tricuspid valve doesn’t close tight enoug ...

Panel of independent experts reviewed data from the TRILUMINATE™ pivotal trial demonstrating safety, effectiveness and quality-of-life benefits of the TriClip system An investigational device in the U.S., TriClip is approved in more than 50 countries and has treated more than 10,000 people with tricuspid regurgitation worldwide ABBOTT PARK, Ill., Feb. 13, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the Circulatory System Devices Panel of the Medical Devices Advisory Committee for the U.S. ...

医疗行业 - Novo Nordisk和Eli Lilly凭借包括Ozempic、Rybelsus、Wegovy、Mounjaro和Zepbound在内的畅销药物在肥胖和糖尿病领域占据主导地位[1] - 制药公司Hims & Hers Health和初创公司Ro也在寻求通过推出自己的GLP-1激动剂版本进入市场[2] Abbott Laboratories - Abbott Laboratories的知名产品包括其营养饮料如Ensure和Pedialyte，以及其婴儿配方奶粉品牌Similac[3] - 公司最新推出的蛋白质饮料Protality可能成为新型糖尿病和肥胖药物的必要补充，也可能成为Abbott的一个有趣的新收入来源[3]

The health sector has two things to offer: new ideas and consistent returns. As a result, healthcare stocks will continue to be a good choice for investors looking for growth opportunities in 2024. The sector is valuable because it has stayed flexible and grown along with improvements in medical tools, treatment methods, and healthcare services all around the world.This rapid rise sparked companies in the sector. It was also expected to raise living standards by offering new medical solutions. So, when we b ...